Remus Pharmaceuticals Ltd (REMUS) — shareholding pattern, promoter holding, financials and share price
About Remus Pharmaceuticals Ltd (REMUS)
Remus Pharmaceuticals Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as REMUS and on the BSE under scrip code 78788. Its ISIN is INE0O5T01011.
Incorporated in 2015, Remus Pharma Ltd is in the business of trading and export of API and Finished Formulations and in Technical consultancy services [1]
Remus Pharmaceuticals Limited is a rapidly growing pharmaceutical company established in 2015, specializing in the marketing and distribution of niche off-patent formulations.
The company operates an asset-light model, boasting a portfolio of over 800 approved products across major therapeutic segments such as oncology and cardiology, and serves more than 40 countries.
Listed peers in Pharmaceuticals: Kopran Ltd, Shree Ganesh Remedies Ltd, Hexagon Nutrition Ltd, Sigachi Industries Ltd, Anlon Healthcare Ltd, Anuh Pharma Ltd.
Valuation & Returns
10 Jul 2026At ₹739.95 a share on 10 Jul 2026, Remus Pharmaceuticals Ltd (REMUS) was valued at a price-to-earnings ratio of 23.57x against an industry P/E of 36.41x and a price-to-book of 2.48x on a book value of ₹297.86 per share. Solomo computes return on equity of 10.54% and return on capital employed of 16.04% from filed results.
- P/E
- 23.57x
- Industry P/E
- 36.41x
- P/B
- 2.48x
- EPS (TTM)
- ₹65.21
- Book value / share
- ₹297.86
- ROE
- 10.54%
- ROCE
- 16.04%
- ROA
- 7.98%
- Debt / equity
- 0.08x
- Dividend yield
- 0.07%
- EBITDA margin
- 7.43%
- 52-week range
- ₹580 – ₹993.95
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Remus Pharmaceuticals Ltd (REMUS) reported revenue of ₹854 crore, net profit of ₹46 crore and earnings per share of ₹31.39. That compares with revenue of ₹620 crore and net profit of ₹38 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹453 crore and net profit ₹25 crore (consolidated).
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Revenue (₹ cr) | 213 | 620 | 854 |
| Net profit (₹ cr) | 24 | 38 | 46 |
| EPS (₹) | 17.69 | 24.64 | 31.39 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 46.03% | 47.40% | 191.33% |
| Profit growth | 89.63% | 79.62% | 58.24% |
| Stock price CAGR | - | 18% | -19% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 70.95% of Remus Pharmaceuticals Ltd (REMUS). Market capitalisation was ₹872 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2023.
Largest disclosed public shareholders in Mar 2026: India Emerging Giants Fund Limited 4.87%, Rekha Gunavanth Kumar 1.09%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 70.95% | - | - | - | - |
| Sep 2025 | 70.91% | - | - | - | - |
| Mar 2025 | 70.85% | - | - | - | - |
| Sep 2024 | 70.84% | - | - | - | - |
| Mar 2024 | 70.6% | - | - | - | - |
| Sep 2023 | 69.61% | - | - | - | - |